Lethal cardiotoxicity, steatohepatitis, chronic pancreatitis, and acute enteritis induced by capecitabine and oxaliplatin in a 36-year-old woman

Diagnostic Pathology

Calin Molnar¹  Leonard Azamfirei³  Zoltan Kadar⁴  Maria Comsulea²  Ioan Jung²  Simona Gurzu² 

[1] Department of Surgery, University of Medicine and Pharmacy of Tirgu-Mures, Tirgu-Mures, Romania;Department of Pathology, University of Medicine and Pharmacy of Tirgu-Mures, Tirgu-Mures, Romania;Intensive Care Unit, University of Medicine and Pharmacy of Tirgu-Mures, Tirgu-Mures, Romania;Department of Oncology, County Hospital of Tirgu-Mures, Tirgu-Mures, Romania

关键词: Pericarditis;    Lethal;    Myocardial fibrosis;    Multiorgan toxicity;    Enteritis;    Steatohepatitis;    Chronic pancreatitis;    Cardiotoxicity;    Oxaliplatin;    Capecitabine;   

Others  :  805188
DOI  :  10.1186/1746-1596-8-150

 received in 2013-05-01, accepted in 2013-08-26,  发布年份 2013

【 摘 要 】

A 36-year-old female was hospitalized with symptoms suggesting intestinal occlusion. She was diagnosed with adenocarcinoma of the ampulla of Vater (pT4N0 stage) and underwent cephalic duodenopancreatectomy 8 months ago. Five cycles of postoperative chemotherapy were administrated using capecitabine and oxaliplatin (CAPOX or XELOX), the last one being completed 1 month ago. During the present hospitalization, because of normal computed tomography and ultrasound abdominal examination, rehydration and antibiotherapy were administrated. However, 4 days after hospital admission, the patient died. At autopsy and histological examination, we found a severe myocardial sclerosis with large scarring areas, severe steatohepatitis, chronic pancreatitis with large fibrotic areas, and acute enteritis. Alcohol consumption was denied. The patient died due to associated heart, liver and pancreatic failure. This multiorgan toxicity and death following CAPOX regimen had not yet been reported in the literature.

【 授权许可】

   
2013 Gurzu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Dekanic A, Dintinjan RD, Budisavljevic I, Pecanic S, Butorac MZ, Jonic N: Strong nuclear EGFR expression in colorectal carcinomas is associated with cyclin-D1 but not with gene EGFR amplification. Diagn Pathol 2011, 6:108. BioMed Central Full Text
• [2]Cartwright TH: Treatment decision after diagnosis of metastatic colorectal cancer. Clin Colorectal Cancer 2012, 11:155-166.
• [3]Butt W, Saadati H, Saif MW: Oxaliplatin-induced pancreatitis: a case series. Anticancer Res 2010, 30:5113-5116.
• [4]Overman MJ, Varadhachary GR, Adinin R, Lin E, Morris JS, Eng C, Abbruzzese JL, Wolff RA: Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowell and ampulla of Vater. J Clin Oncol 2009, 27:2598-2603.
• [5]Chan HY, Ng CM, Tiu SC, Chan AOK, Shek CC: Hypertrigliceridaemia-induced pancreatitis: a contributory role of capecitabine? Hong Kong Med J 2012, 18:526-529.
• [6]Wangefjord S, Brandstedt J, Lindquist KE, Nodin B, Jirstrom K, Eberhard J: Associations of beta-catenin alterations and MSI screening status with expression of key cell ceycle regulating proteins and survival form colorectal cancer. Diagn Pathol 2013, 8:10. BioMed Central Full Text
• [7]Yucel H, Warmerdam LV: Capecitabine-induced pancreatitis. J Oncol Pharm Pract 2010, 16:133-134.
• [8]Michie CO, Sakala M, Rivans I, Strachan MWJ, Clive S: The frequency and severity of capecitabine-induced hypertriglyceridaemia in routine clinical practice: a prospective study. Br J Cancer 2010, 103:617-621.
• [9]Y-Hassan S, Tornvall P, Tornerud M, Henareh L: Capecitabine caused cardiogenic shock through induction of global takotsubo syndrome. Cardiovasc Revasc Med 2013, 14:57-61.
• [10]Manojlovic N, Babic D, Stojanovic S, Filipovic I, Radoje D: Capecitabine cardiotoxicity - case reports and literature review. Hepatogastroenterology 2008, 55:1249-1256.
• [11]Jones KL, Valero V: Capecitabine-induced pancreatitis. Pharmacotherapy 2003, 23:1076-1078.
• [12]Stathopoulos GP, Koutantos J, Lazaki H, Rigatos SK, Stathopoulos J, Deliconstantinos G: Capecitabine (Xeloda) as monotherapy in advanced breast and colorectal cancer: effectiveness and side-effects. Anticancer Res 2007, 27:1653-1656.
• [13]Pessaux P: Chemotherapy’s hepatotoxicity: what is the impact on surgery? J Chir (Paris) 2010, 147(Suppl 1):S7-S11.
• [14]Vincenzi B, Daniele S, Frezza AM, Berti P, Vespasiani U, Picardi A, Tonini G: The role of S-adenosylmethionine in preventing oxaliplatin-induced liver toxicity: a retrospective analysis in metastatic colorectal cancer patients treated with bevacizumab plus oxaliplatin-based regimen. Support Care Cancer 2012, 20:135-139.
• [15]Luo S, Zhang X, Yu M, Yan H, Liu H, Wilson JH, Huang G: Folic acid acts through DNA methyltransferases to induce the differentiation of neural stem cells into neurons. Cell Biochem Biophys 2013, 66:559-566.
• [16]Sanoff HK, Bernard S, Goldberg RM, Morse MA, Garcia R, Woods L, Moore DT, O’Neill BH: Phase II study of capecitabine, oxaliplatin, and cetuximab for advanced hepatocellular carcinoma. Gastrointest Cancer Res 2011, 4:78-83.
• [17]Bouma G, Imholz AL: Ileitis following capecitabine use. Ned Tijdschr Geneeskd 2011, 155:A3064.